1. Basic Information
Disease Overview
- Japanese Encephalitis (JE): Mosquito-borne flavivirus (Culex species vectors, amplified in pigs and wading birds), endemic across most of Asia and parts of the Western Pacific. Most infections are asymptomatic (<1% develop encephalitis), but among those with symptomatic encephalitis, case-fatality is 20–30%, and 30–50% of survivors have long-term neuropsychiatric sequelae. It is the leading vaccine-preventable cause of encephalitis in Asia.
Recommended Use
| Population | Recommendation |
|---|---|
| Travelers ≥1 month in endemic rural areas during transmission season | 2-dose primary series, days 0 and 28 (accelerated 1-week schedule available for adults 18–65) |
| Shorter-term travelers with high-risk activities | Outdoor/rural/agricultural exposure, or uncertain itinerary, may still warrant vaccination per individualized risk assessment |
| Booster | Single booster at ≥1 year if ongoing/future JE exposure risk continues |
| Age range (U.S. product) | Licensed for age ≥2 months |
Source: CDC Yellow Book; ACIP JE vaccine recommendations (2019 update).
Licensed Products
- IXIARO® (Valneva) — inactivated, Vero-cell-derived. Licensed in the U.S. since 2009 (adults) and 2013 (children ≥2 months). Replaced the older mouse-brain-derived JE-VAX, discontinued in the U.S. in 2011.
- SA14-14-2 (live-attenuated) — used in China, India, and other endemic-country national immunization programs (e.g., part of China's EPI schedule); not licensed in the U.S.
2. Pre-Licensure Clinical Trial Data
IXIARO's licensure was supported by immunogenicity (non-inferiority to the older JE-VAX) and safety trials in adults and children across the U.S., Europe, and endemic Asian countries.
| Metric | Data | Evidence Strength |
|---|---|---|
| Seroconversion after 2-dose primary series | >95% across adult and pediatric immunogenicity trials | Strong |
| Pediatric safety database | ~JE-endemic-country pediatric trials totaling several thousand children supported the 2013 pediatric licensure | Moderate |
| Direct clinical efficacy (disease endpoint) trial | Not conducted (immunogenicity-based licensure, standard for JE vaccines given low absolute incidence in any single trial population) | Limited |
Key Limitations
- Immunogenicity-based licensure: Like several travel vaccines, IXIARO's approval relies on antibody response as a correlate of protection rather than a direct disease-endpoint efficacy trial, since JE incidence in any feasible trial population/travel cohort is too low to power such a study.
- Long-term durability beyond the 1-year booster point is less well characterized than for some routine childhood vaccines, given the vaccine's relatively recent (2009) introduction.
3. Post-Licensure Safety Data
Post-Licensure Safety Monitoring
A CDC/FDA review of VAERS reports from IXIARO's first several years on the U.S. market (2013 review covering 2009–2012) did not identify an unusual or unexpected adverse event pattern compared to other inactivated travel vaccines.
| Metric | Finding |
|---|---|
| VAERS review (2009–2012 U.S. data) | No unusual safety signal identified; reports dominated by injection site and mild systemic reactions |
| Comparison to older JE-VAX | IXIARO has a substantially improved reactogenicity and allergy profile compared to the discontinued mouse-brain-derived JE-VAX, which had higher rates of delayed urticarial/allergic reactions |
⚠ Critical Caveat
VAERS data represent unverified reports temporally associated with vaccination and cannot establish causality or incidence rates on their own.
4. Documented Adverse Events — Evidence of Association
▶ Strong Evidence of Causal Association
- Injection site pain/tenderness: Common, ~30–60%. Self-limited. Strong
- Headache, myalgia, fatigue: ~20–30%. Self-limited. Strong
- Anaphylaxis: Rare, consistent with other inactivated injectable vaccines. Strong
▶ Moderate or Preliminary Evidence
- Delayed urticaria (older JE-VAX, historical): Documented with the discontinued mouse-brain-derived vaccine; not seen at meaningfully elevated rates with the current Vero-cell IXIARO product. Limited (legacy vaccine)
5. Disease Prevention Benefits
Program Impact (Endemic-Country Live-Vaccine Programs)
| Country/Program | Outcome |
|---|---|
| China (SA14-14-2, national EPI) | Routine childhood JE vaccination since the 1980s–2000s associated with major declines in reported pediatric JE incidence |
| India (endemic districts) | Campaign and routine SA14-14-2 vaccination in high-burden districts associated with sharp reductions in encephalitis hospitalizations attributable to JE |
| Traveler protection (IXIARO) | No large-scale traveler effectiveness studies exist due to the rarity of JE in short-term travelers, but seroprotection correlates strongly predict clinical protection based on decades of field experience with JE vaccines generally |
Source: WHO JE position paper (2015); national surveillance summaries (China CDC, India NVBDCP).
6. Evidence Summary
IXIARO provides strong, well-documented immunogenicity against a disease with high case-fatality and disability among the small fraction of infections that become symptomatic. Its safety profile is favorable and represents a substantial improvement over the discontinued mouse-brain-derived predecessor vaccine. The main evidence gap, shared by most travel vaccines, is the absence of a direct disease-endpoint efficacy trial.
| Domain | Evidence Grade | Key Finding |
|---|---|---|
| Immunogenicity | Strong | >95% seroconversion after 2-dose series |
| Reactogenicity | Strong | Mostly mild, self-limited local/systemic reactions |
| Direct efficacy (disease endpoint) | Limited | Licensure based on immunogenicity, not disease-endpoint RCT |
| Serious safety signal | No Association | No unusual pattern in post-licensure VAERS review |
7. Key References
- WHO. Japanese encephalitis vaccines: WHO position paper. Wkly Epidemiol Rec. 2015;90(9):69–87.
- CDC. Japanese Encephalitis. CDC Yellow Book, Travelers’ Health. cdc.gov/yellowbook
- Hills SL, et al. Japanese Encephalitis Vaccine: Recommendations of ACIP. MMWR Recomm Rep. 2019;68(2):1–33.
- Schuller E, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine. Vaccine. 2008;26(37):4382–4386.